MX2017014163A - Moduladores de k-ras. - Google Patents
Moduladores de k-ras.Info
- Publication number
- MX2017014163A MX2017014163A MX2017014163A MX2017014163A MX2017014163A MX 2017014163 A MX2017014163 A MX 2017014163A MX 2017014163 A MX2017014163 A MX 2017014163A MX 2017014163 A MX2017014163 A MX 2017014163A MX 2017014163 A MX2017014163 A MX 2017014163A
- Authority
- MX
- Mexico
- Prior art keywords
- ras
- ras modulators
- modulators
- inhibiting
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan en la presente, entre otros, métodos y compuestos para la inhibición de K-Ras y para el tratamiento del cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562157915P | 2015-05-06 | 2015-05-06 | |
US201562158356P | 2015-05-07 | 2015-05-07 | |
PCT/US2016/031344 WO2016179558A1 (en) | 2015-05-06 | 2016-05-06 | K-ras modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014163A true MX2017014163A (es) | 2018-08-15 |
Family
ID=57218009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014163A MX2017014163A (es) | 2015-05-06 | 2016-05-06 | Moduladores de k-ras. |
Country Status (17)
Country | Link |
---|---|
US (2) | US10857140B2 (es) |
EP (1) | EP3291813A4 (es) |
JP (1) | JP6771023B2 (es) |
KR (1) | KR20180017013A (es) |
CN (1) | CN107847495A (es) |
AU (1) | AU2016258192B2 (es) |
BR (1) | BR112017023821A2 (es) |
CA (1) | CA2983927A1 (es) |
CL (2) | CL2017002786A1 (es) |
EA (1) | EA201792443A1 (es) |
EC (1) | ECSP17073743A (es) |
HK (2) | HK1251485A1 (es) |
IL (1) | IL255417A (es) |
MA (1) | MA42061A (es) |
MX (1) | MX2017014163A (es) |
PH (1) | PH12017501999A1 (es) |
WO (1) | WO2016179558A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104379563B (zh) * | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
KR20180017013A (ko) | 2015-05-06 | 2018-02-20 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | K-Ras 조절제 |
CA3024523A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
AU2018255413A1 (en) | 2017-04-20 | 2019-12-05 | Leidos Biomedical Research, Inc. | K-Ras modulators |
US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
HUE061599T2 (hu) | 2017-11-15 | 2023-07-28 | Mirati Therapeutics Inc | KRas G12C inhibotorok |
WO2019204505A2 (en) * | 2018-04-18 | 2019-10-24 | Theras, Inc. | K-ras modulators with a vinyl sulfonamide moiety |
WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
WO2020198488A1 (en) * | 2019-03-26 | 2020-10-01 | University Of Massachusetts | Therapeutic targets for oncogenic kras-dependent cancers |
JP2022546043A (ja) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12d阻害剤 |
MX2022003537A (es) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
CN110981943B (zh) * | 2019-12-02 | 2021-08-03 | 清华大学 | 多肽及其在制备药物中的用途和药物 |
MX2022007515A (es) | 2019-12-20 | 2022-09-19 | Mirati Therapeutics Inc | Inhibidores de sos1. |
IL297650A (en) * | 2020-04-27 | 2022-12-01 | Verastem Inc | Methods for treating abnormal cell growth |
TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3131527A1 (de) | 1981-08-08 | 1983-02-24 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
JPS61227567A (ja) * | 1985-04-01 | 1986-10-09 | Eisai Co Ltd | 1,4−ジヒドロピリジン誘導体 |
DK626889A (da) | 1988-12-16 | 1990-06-17 | Roussel Uclaf | Indanderivater, deres fremstilling samt laegemidler med indhold deraf |
IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
WO1996006078A1 (en) | 1994-08-24 | 1996-02-29 | Pfizer Pharmaceuticals Inc. | N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists |
US5475109A (en) * | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
US5631251A (en) | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
JP2003501414A (ja) | 1999-06-04 | 2003-01-14 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼの阻害剤 |
CN1373662A (zh) | 1999-08-12 | 2002-10-09 | 法玛西雅意大利公司 | 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途 |
US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
WO2003004474A1 (en) | 2001-07-06 | 2003-01-16 | Syngenta Participations Ag | Pesticidally active aminoacetonitriles |
AU2003269242A1 (en) | 2002-10-11 | 2004-05-04 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
EA009469B1 (ru) * | 2003-03-12 | 2007-12-28 | Кудос Фармасеутикалс Лимитед | Производные фталазинона |
US20050119266A1 (en) | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
GB0326029D0 (en) * | 2003-11-07 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
JPWO2005047286A1 (ja) | 2003-11-13 | 2007-05-31 | 小野薬品工業株式会社 | スピロ複素環化合物 |
US20080058356A1 (en) | 2003-12-15 | 2008-03-06 | Neurocrine Biosciences, Inc. | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists |
ATE443701T1 (de) | 2004-01-16 | 2009-10-15 | Wyeth Corp | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion |
CA2640807A1 (en) * | 2006-02-17 | 2007-08-23 | F. Hoffmann-La Roche Ag | Benzoyl-piperidine derivatives as 5ht2/d3 modulators |
CA2645652A1 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
WO2009015237A1 (en) | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
US8383659B2 (en) | 2008-12-19 | 2013-02-26 | Novartis Ag | Isoxazoline derivatives as pesticides |
TWI671297B (zh) | 2009-05-27 | 2019-09-11 | Ptc治療公司 | 治療癌症及非腫瘤病症之方法 |
US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
CN104379563B (zh) * | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
EP2698367A1 (en) | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
WO2014093230A2 (en) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
EP2970121B1 (en) * | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
WO2015048570A2 (en) * | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Ebi2 modulators |
EP3277678B1 (en) * | 2015-04-03 | 2020-03-18 | NantBio, Inc. | Compositions and methods of targeting mutant k-ras |
KR20180017013A (ko) | 2015-05-06 | 2018-02-20 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | K-Ras 조절제 |
CA3021062A1 (en) | 2016-04-15 | 2017-10-19 | Epizyme, Inc. | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
AU2018255413A1 (en) | 2017-04-20 | 2019-12-05 | Leidos Biomedical Research, Inc. | K-Ras modulators |
-
2016
- 2016-05-06 KR KR1020177035079A patent/KR20180017013A/ko unknown
- 2016-05-06 EA EA201792443A patent/EA201792443A1/ru unknown
- 2016-05-06 WO PCT/US2016/031344 patent/WO2016179558A1/en active Application Filing
- 2016-05-06 CN CN201680037365.9A patent/CN107847495A/zh active Pending
- 2016-05-06 AU AU2016258192A patent/AU2016258192B2/en not_active Ceased
- 2016-05-06 EP EP16790206.3A patent/EP3291813A4/en not_active Withdrawn
- 2016-05-06 JP JP2018510695A patent/JP6771023B2/ja active Active
- 2016-05-06 CA CA2983927A patent/CA2983927A1/en not_active Abandoned
- 2016-05-06 MX MX2017014163A patent/MX2017014163A/es unknown
- 2016-05-06 US US15/571,475 patent/US10857140B2/en active Active
- 2016-05-06 MA MA042061A patent/MA42061A/fr unknown
- 2016-05-06 BR BR112017023821A patent/BR112017023821A2/pt not_active Application Discontinuation
-
2017
- 2017-11-02 PH PH12017501999A patent/PH12017501999A1/en unknown
- 2017-11-03 CL CL2017002786A patent/CL2017002786A1/es unknown
- 2017-11-03 IL IL255417A patent/IL255417A/en unknown
- 2017-11-06 EC ECIEPI201773743A patent/ECSP17073743A/es unknown
-
2018
- 2018-08-30 HK HK18111150.3A patent/HK1251485A1/zh unknown
- 2018-09-04 HK HK18111290.4A patent/HK1251972A1/zh unknown
- 2018-11-21 CL CL2018003316A patent/CL2018003316A1/es unknown
-
2020
- 2020-10-28 US US17/082,125 patent/US11541044B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ECSP17073743A (es) | 2018-03-31 |
US20180289683A1 (en) | 2018-10-11 |
CA2983927A1 (en) | 2016-11-10 |
US11541044B2 (en) | 2023-01-03 |
CL2017002786A1 (es) | 2018-06-22 |
EA201792443A1 (ru) | 2018-10-31 |
IL255417A (en) | 2018-01-31 |
MA42061A (fr) | 2021-03-31 |
CN107847495A (zh) | 2018-03-27 |
EP3291813A1 (en) | 2018-03-14 |
US20210196695A1 (en) | 2021-07-01 |
AU2016258192B2 (en) | 2021-07-29 |
WO2016179558A1 (en) | 2016-11-10 |
US10857140B2 (en) | 2020-12-08 |
JP6771023B2 (ja) | 2020-10-21 |
KR20180017013A (ko) | 2018-02-20 |
CL2018003316A1 (es) | 2019-03-15 |
WO2016179558A8 (en) | 2017-11-16 |
HK1251972A1 (zh) | 2019-05-10 |
EP3291813A4 (en) | 2019-01-02 |
PH12017501999A1 (en) | 2018-04-02 |
BR112017023821A2 (pt) | 2018-07-31 |
JP2018519357A (ja) | 2018-07-19 |
HK1251485A1 (zh) | 2019-02-01 |
AU2016258192A1 (en) | 2017-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501999A1 (en) | K-ras modulators | |
MX2019012532A (es) | Moduladores de k-ras. | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
EP3641770A4 (en) | METHOD OF TREATMENT OF CANCER | |
MX2019005076A (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2. | |
EP3488001A4 (en) | TREATMENT OF CANCER | |
IL263497B (en) | 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment | |
EP3288382A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
EP3180010A4 (en) | Combination therapy for treating cancer | |
AU2019268074A1 (en) | Methods for treating hepcidin-mediated disorders | |
EP3407978A4 (en) | COMBINATION THERAPY FOR TREATING CANCER | |
EP3285773A4 (en) | POLY THERAPY FOR THE TREATMENT OF CANCER | |
EP3362066A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
EP3621592A4 (en) | POLYTHERAPIES FOR CANCER TREATMENT | |
MX2020003770A (es) | Terapias de combinacion para tratar cancer. | |
EP3405203A4 (en) | METHODS OF TREATING CANCER | |
EP3389634A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
EP3341080A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
EP3440112A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
EP3193884A4 (en) | Combination therapy for treating cancer | |
EP3359255A4 (en) | POLYTHERAPIES FOR THE TREATMENT OF CANCER | |
EP3362065A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
EP3389652A4 (en) | METHODS OF TREATING CANCER | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. |